Across TCGA pan-cancer cohorts, VSTM2B mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated VSTM2B data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher VSTM2B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated VSTM2B expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM are the cancer types where VSTM2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.908	0.589	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: VSTM2B tumor-vs-normal RNA expression · all VSTM2B data types